# A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

> **NCT03628924** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 184 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Guselkumab dose 1
- **DRUG:** Guselkumab dose 2
- **DRUG:** Guselkumab dose 3
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03628924
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-04
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03628924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03628924, "A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03628924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*